

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM864432

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Journey Medical Corporation		12/27/2023	Corporation: DELAWARE
JG Pharma, Inc.		12/27/2023	Corporation: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	SWK Funding LLC
<b>Street Address:</b>	5956 Sherry Lane, Suite 650
<b>City:</b>	Dallas
<b>State/Country:</b>	TEXAS
<b>Postal Code:</b>	75225
<b>Entity Type:</b>	Limited Liability Company: DELAWARE

## PROPERTY NUMBERS Total: 22

Property Type	Number	Word Mark
Registration Number:	5788124	ACCUTANE
Registration Number:	6024563	AMZEEQ
Registration Number:	6034819	AMZEEQ
Registration Number:	6034820	
Registration Number:	5227868	EURAX
Registration Number:	0434497	EURAX
Serial Number:	88308081	MST
Serial Number:	90892398	MST
Registration Number:	5069478	JOURNEY MEDICAL CORPORATION
Registration Number:	5027634	JOURNEY MEDICAL CORPORATION
Registration Number:	5101104	TARGADOX
Registration Number:	5096340	TARGADOX
Registration Number:	5370300	XIMINO
Registration Number:	6084244	CAPSULAR MINOTAB TECHNOLOGY
Registration Number:	5096785	CERACADE
Registration Number:	5042776	LUXAMEND
Registration Number:	6235231	ZILXI
Registration Number:	6223434	

OP \$565.00 5788124

Property Type	Number	Word Mark
Registration Number:	6223436	
Registration Number:	5639520	QBREXZA
Registration Number:	1206693	EXELDERM
Registration Number:	6505432	

**CORRESPONDENCE DATA**

**Fax Number:** 6175236850  
*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*  
**Phone:** 617-523-2700  
**Email:** susan.dinicola@hkllaw.com, ana-victoria.moreno@hkllaw.com  
**Correspondent Name:** Holland & Knight LLP  
**Address Line 1:** 10 St. James Avenue  
**Address Line 4:** Boston, MASSACHUSETTS 02116

<b>NAME OF SUBMITTER:</b>	Susan C. DiNicola
<b>SIGNATURE:</b>	/Susan C. DiNicola/
<b>DATE SIGNED:</b>	12/28/2023

**Total Attachments: 37**  
source=Journey Intellectual Property Security Agreement#page1.tif  
source=Journey Intellectual Property Security Agreement#page2.tif  
source=Journey Intellectual Property Security Agreement#page3.tif  
source=Journey Intellectual Property Security Agreement#page4.tif  
source=Journey Intellectual Property Security Agreement#page5.tif  
source=Journey Intellectual Property Security Agreement#page6.tif  
source=Journey Intellectual Property Security Agreement#page7.tif  
source=Journey Intellectual Property Security Agreement#page8.tif  
source=Journey Intellectual Property Security Agreement#page9.tif  
source=Journey Intellectual Property Security Agreement#page10.tif  
source=Journey Intellectual Property Security Agreement#page11.tif  
source=Journey Intellectual Property Security Agreement#page12.tif  
source=Journey Intellectual Property Security Agreement#page13.tif  
source=Journey Intellectual Property Security Agreement#page14.tif  
source=Journey Intellectual Property Security Agreement#page15.tif  
source=Journey Intellectual Property Security Agreement#page16.tif  
source=Journey Intellectual Property Security Agreement#page17.tif  
source=Journey Intellectual Property Security Agreement#page18.tif  
source=Journey Intellectual Property Security Agreement#page19.tif  
source=Journey Intellectual Property Security Agreement#page20.tif  
source=Journey Intellectual Property Security Agreement#page21.tif  
source=Journey Intellectual Property Security Agreement#page22.tif  
source=Journey Intellectual Property Security Agreement#page23.tif  
source=Journey Intellectual Property Security Agreement#page24.tif  
source=Journey Intellectual Property Security Agreement#page25.tif  
source=Journey Intellectual Property Security Agreement#page26.tif

source=Journey Intellectual Property Security Agreement#page27.tif  
source=Journey Intellectual Property Security Agreement#page28.tif  
source=Journey Intellectual Property Security Agreement#page29.tif  
source=Journey Intellectual Property Security Agreement#page30.tif  
source=Journey Intellectual Property Security Agreement#page31.tif  
source=Journey Intellectual Property Security Agreement#page32.tif  
source=Journey Intellectual Property Security Agreement#page33.tif  
source=Journey Intellectual Property Security Agreement#page34.tif  
source=Journey Intellectual Property Security Agreement#page35.tif  
source=Journey Intellectual Property Security Agreement#page36.tif  
source=Journey Intellectual Property Security Agreement#page37.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of December 27, 2023 (as may be amended, restated, amended and restated, waived, supplemented, or otherwise modified from time to time, this “Agreement”), made by JOURNEY MEDICAL CORPORATION, a Delaware corporation and JG PHARMA, INC., a Delaware corporation (each a “Grantor” and collectively the “Grantors”), in favor of SWK FUNDING LLC, a Delaware limited liability company as agent (in such capacity, “Agent”) for the Lenders (as defined below) party to the Credit Agreement (as defined below).

### W I T N E S S E T H:

WHEREAS, pursuant to that certain Credit Agreement, dated as of December 27, 2023 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among Journey Medical Corporation (“Borrower”), Agent and the financial institutions party thereto from time to time as lenders (each a “Lender” and collectively, the “Lenders”), Agent and Lenders have agreed to make certain financial accommodations available to Borrower, and pursuant to that certain Guarantee and Collateral Agreement, dated on or about the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Guarantee and Collateral Agreement”), by and among the Grantors, the other grantors party thereto from time to time, and Agent, each Grantor has guaranteed the repayment of the amounts owed pursuant to the Credit Agreement and has granted a security interest to Agent, for the benefit of Agent and Lenders, in, among other things, all right, title and interest of such Grantor in, to and under all of such Grantor’s Intellectual Property (as defined in the Credit Agreement), whether now existing or hereafter arising or acquired as security for the Obligations; and

WHEREAS, Each Grantor is the owner of the entire right, title and interest in, to and under the Intellectual Property listed on Schedule I hereto, as applicable.

NOW, THEREFORE, in consideration of the premises and to induce Agent and Lenders to enter into the Credit Agreement, each Grantor hereby agrees with Agent as follows:

#### 1. Defined Terms.

(a) Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided in the Guarantee and Collateral Agreement.

#### (b) Other Definitional Provisions.

(i) The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and section and paragraph references are to this Agreement unless otherwise specified.

(ii) The meanings given to terms defined herein shall be equally applicable to both the singular and plural forms of such terms.

2. Grant of Security Interest. To secure the payment and performance of the Secured Obligations, each Grantor hereby confirms and acknowledges that it has granted (and, to the extent not previously granted under the Guarantee and Collateral Agreement, does hereby grant) to Agent, for the benefit of Agent and Lenders, a lien and security interest in such Grantor’s entire right, title and interest in its Intellectual Property and all proprietary rights relating to or arising from such Intellectual Property, in

each case whether now owned or hereafter acquired by such Grantor, and including, without limitation, such Grantor's right, title and interest in and to the Intellectual Property and proprietary rights identified on Schedule I attached hereto and made a part hereof, and the right to sue for past, present and future infringements and dilutions, and all rights corresponding thereto throughout the world, and the entire goodwill of such Grantor's business connected with and symbolized by such Intellectual Property and all income, fees, royalties, proceeds and other payments at any time due or payable with respect to any of the foregoing (referred to collectively as the "IP Collateral"); provided, that the IP Collateral shall not include the Excluded Property. This Agreement is not to be construed as an assignment of any Intellectual Property.

3. **No Limitation; Loan Documents.** This Agreement has been executed and delivered by each Grantor for the purpose of recording the security interest granted to Agent with respect to the IP Collateral with the United States Patent and Trademark Office, the United States Copyright Office, as well as with any similar office or department of any other foreign or domestic Governmental Authority. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to Agent, for the benefit of Agent and Lenders, under the Guarantee and Collateral Agreement and the other Loan Documents, and each Grantor hereby acknowledges and affirms that the rights and remedies of the Agent with respect to the security interest in the IP Collateral made and granted hereby are more fully set forth in the Guarantee and Collateral Agreement. The other Loan Documents (and all rights and remedies of Grantors, Agent, and Lenders thereunder) shall remain in full force and effect in accordance with their terms.

4. **Binding Effect; Benefits.** This Agreement shall be binding upon each Grantor and its successors and assigns, and shall inure to the benefit of Agent, Lenders and their respective successors and assigns.

5. **GOVERNING LAW. THIS AGREEMENT SHALL BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE.**

6. **Counterparts; Electronic Signatures.** This Agreement may be executed in counterparts with the same effect as if all parties had executed the same document. All counterparts shall be construed together and shall constitute a single agreement. Further, the parties hereto consent and agree that this Agreement may be signed and/or transmitted by e-mail of any .pdf file, .jpeg file, or any other electronic or image file, or any "electronic signature" as defined under the U.S. Electronic Signatures in Global and National Commerce Act or the New York Electronic Signatures and Records Act, which includes any electronic signature provided using Orbit, Adobe Sign, DocuSign, or any other similar platform identified by the parties hereto and reasonably available at no undue burden or expense to the Agent), except to the extent the Agent requires otherwise. Any such electronic signatures shall be valid, effective and legally binding as if such electronic signatures were handwritten signatures and shall be deemed to have been duly and validly delivered for all purposes hereunder. No party hereto shall raise the use of e-mail or other electronic transmission to deliver a signature or the fact that any signature or agreement or amendment was transmitted or communicated through the use of e-mail or other electronic transmission as a defense to the formation or enforceability of a contract and each such party forever waives any such defense.

7. **Conflicting Terms.** In the event of any conflict or inconsistency between the terms of this Agreement and the terms of the Credit Agreement or the Guarantee and Collateral Agreement, as the case may be, the terms of the Credit Agreement or the Guarantee and Collateral Agreement, as applicable, shall control.

**IN WITNESS WHEREOF**, the parties have caused this Intellectual Property Security Agreement to be executed by its duly authorized representatives as of the date first above written.

**GRANTORS:**

**JOURNEY MEDICAL CORPORATION**, a Delaware corporation

By: **Claude Maraoui**

Name: Claude Maraoui

Title: Chief Executive Officer

**JG PHARMA, INC.**, a Delaware corporation

By: **Claude Maraoui**

Name: Claude Maraoui


Title: Chief Executive Officer

**AGENT:**

**SWK FUNDING LLC**, a Delaware limited liability company, as Agent and a Lender

By: SWK Holdings Corporation, a Delaware corporation, its sole Manager

DocuSigned by:

By:  \_\_\_\_\_  
E9D13E6EA4E94A7...

Name: Joe D. Staggs

Title: President and Chief Executive Officer

**Schedule I**

**Patents**

See attached.



**Owned Patents**

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
USA	GRANTED	13/781390	02/28/2013	8558008	10/15/2013	US-2013-0211101-A1	08/15/2013	CRYSTALLINE GLYCOPYRROLATE TOSYLATE
USA	GRANTED	14/024480	09/11/2013	9006461	04/14/2015	US-2014-0243535-A1	08/28/2014	CRYSTALLINE GLYCOPYRROLATE TOSYLATE
USA	GRANTED	14/024484	09/11/2013	8859610	10/14/2014	US-2014-0242122-A1	08/28/2014	CRYSTALLINE GLYCOPYRROLATE TOSYLATE
USA	GRANTED	14/473537	08/29/2014	9006462	04/14/2015	US-2014-0371290-A1	12/18/2014	GLYCOPYRROLATE SALTS
USA	GRANTED	14/643553	03/10/2015	9259414	02/16/2016	US-2015-0196532-A1	04/16/2015	GLYCOPYRROLATE SALTS
USA	GRANTED	14/989995	01/07/2016	9610278	04/04/2017	US-2016-0113902-A1	04/28/2016	GLYCOPYRROLATE SALTS
USA	GRANTED	15/438636	02/21/2017	10004717	06/26/2018	US-2017-0157088-A1	06/08/2017	GLYCOPYRROLATE SALTS
USA	GRANTED	15/996353	06/01/2018	10543192	01/28/2020	US-2018-0271833-A1	09/27/2018	GLYCOPYRROLATE SALTS
USA	GRANTED	16/235120	12/28/2018	10548875	02/04/2020	US-2019-0133999-A1	05/09/2019	GLYCOPYRROLATE SALTS
USA	GRANTED	16/737747	01/08/2020	11291651	04/05/2022	US-2020-138778-A1	05/07/2020	GLYCOPYRROLATE SALTS
USA	GRANTED	16/917677	06/30/2020	11291652	04/05/2022	US-2020-0330430-A1	10/22/2020	GLYCOPYRROLATE SALTS
AUSTRALIA	GRANTED	2014223172	02/28/2014	2014223172	12/22/2016			GLYCOPYRROLATE SALTS
AUSTRALIA	GRANTED	2016269524	02/28/2014	2016269524	01/03/2019			GLYCOPYRROLATE SALTS
CANADA	GRANTED	2902795	02/28/2014	2902795	06/15/2021	2902795	09/04/2014	GLYCOPYRROLATE SALTS
EPO PATENT	GRANTED	14716654.0	02/28/2014	2961734	09/26/2018	2961734	01/06/2016	GLYCOPYRROLATE SALTS
EPO PATENT	GRANTED	02729682.1	05/07/2002	1471879	01/02/2013	1471879	11/03/2004	OPPOSITION (UNFILED): TOPICAL GLYCOPYRROLATE PRODUCT
HONG KONG	GRANTED	16100407.9	02/28/2014	HK1212350	09/06/2019	1212350A	06/10/2016	GLYCOPYRROLATE SALTS

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
HONG KONG	GRANTED	19131303.0	02/28/2014	40011324	06/16/2023	40011324	07/17/2020	GLYCOPYRROLATE SALTS
JAPAN	GRANTED	2015-560369	02/28/2014	6114841	03/24/2017	P2016-510037A	04/04/2016	GLYCOPYRROLATE SALTS
JAPAN	GRANTED	2017-052971	02/28/2014	6379246	08/03/2018	P2017-128593A	07/27/2017	GLYCOPYRROLATE SALTS
KOREA (SOUTH)	GRANTED	10-2019-7033311	02/28/2014	10-2232806	03/22/2021	10-2019-0138676	12/13/2019	GLYCOPYRROLATE SALTS
KOREA (SOUTH)	GRANTED	10-2021-7008447	02/28/2014	10-2377252	03/17/2022	10-2021-0034691	03/30/2021	GLYCOPYRROLATE SALTS
MEXICO	GRANTED	MX/A/2016/010800	02/28/2014	372179	03/11/2020			GLYCOPYRROLATE SALTS
NEW ZEALAND	GRANTED	710740	02/28/2014	710740	09/29/2020			GLYCOPYRROLATE SALTS
SINGAPORE	GRANTED	11201506789P	02/28/2014	11201506789P	06/24/2016		09/29/2015	GLYCOPYRROLATE SALTS
SOUTH AFRICA	GRANTED	2015/05625	02/28/2014	2015/05625	10/31/2018			GLYCOPYRROLATE SALTS
SWITZERLAND	GRANTED	14716654.0	02/28/2014	2961734	09/26/2018	2961734	01/06/2016	GLYCOPYRROLATE SALTS
GERMANY	GRANTED	14716654.0	02/28/2014	2961734	09/26/2018	2961734	01/06/2016	GLYCOPYRROLATE SALTS
SPAIN	GRANTED	14716654.0	02/28/2014	2961734	09/26/2018	2961734	01/06/2016	GLYCOPYRROLATE SALTS
FRANCE	GRANTED	14716654.0	02/28/2014	2961734	09/26/2018	2961734	01/06/2016	GLYCOPYRROLATE SALTS
UNITED KINGDOM	GRANTED	14716654.0	02/28/2014	2961734	09/26/2018	2961734	01/06/2016	GLYCOPYRROLATE SALTS
IRELAND	GRANTED	14716654.0	02/28/2014	2961734	09/26/2018	2961734	01/06/2016	GLYCOPYRROLATE SALTS
ITALY	GRANTED	502018000038801	02/28/2014	2961734	09/26/2018	2961734	01/06/2016	GLYCOPYRROLATE SALTS
USA	GRANTED	15/895685	02/13/2018	10294201	05/21/2019	US-2018-0186735-A1	07/05/2018	PROCESS FOR PRODUCTION OF GLYCOPYRRONUM TOSYLATE
USA	GRANTED	16/798160	02/21/2020	11542232	01/03/2023	US-2021-0002219-A1	01/07/2021	PROCESS FOR PRODUCTION OF GLYCOPYRRONUM TOSYLATE
USA	GRANTED	14/869799	09/29/2015	9440056	09/13/2016	US-2016-0089526-A1	03/31/2016	DEVICE AND METHOD FOR DISPENSING A DRUG
USA	GRANTED	15/146627	05/04/2016	10092736	10/09/2018	US-2016-0243345-A1	08/25/2016	DEVICE AND METHOD FOR DISPENSING A DRUG
AUSTRALIA	GRANTED	2015323863	09/29/2015	2015323863	10/15/2020			DEVICE AND METHOD FOR DISPENSING A DRUG
CANADA	GRANTED	2962947	09/29/2015	2962947	02/23/2021	2962947		DEVICE AND METHOD FOR DISPENSING A DRUG
CHINA	GRANTED	201580064668.5	09/29/2015	ZL201580064668.5	10/13/2020	107106826	08/29/2017	DEVICE AND METHOD FOR DISPENSING A DRUG

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
EPO PATENT	GRANTED	15779121.1	09/29/2015	3200863	11/04/2020	3200863	08/09/2017	DEVICE AND METHOD FOR DISPENSING A DRUG
ISRAEL	GRANTED	251395	09/29/2015	251395	12/01/2020		08/31/2020	DEVICE AND METHOD FOR DISPENSING A DRUG
JAPAN	GRANTED	2017-515914	09/29/2015	6684272	03/31/2020	P2017-534331A	11/27/2017	DEVICE AND METHOD FOR DISPENSING A DRUG
KOREA (SOUTH)	GRANTED	10-2017-7008899	09/29/2015	1923331	11/22/2018	10-2017-0048519	05/08/2017	DEVICE AND METHOD FOR DISPENSING A DRUG
MEXICO	GRANTED	MX/A/2017/004053	09/29/2015	381830	04/22/2021		08/17/2018	DEVICE AND METHOD FOR DISPENSING A DRUG
NEW ZEALAND	GRANTED	731349	09/29/2015	731349	10/04/2022			DEVICE AND METHOD FOR DISPENSING A DRUG
SINGAPORE	GRANTED	11201702485S	09/29/2015	11201702485S	02/09/2020		04/27/2017	DEVICE AND METHOD FOR DISPENSING A DRUG
SOUTH AFRICA	GRANTED	2017/01970	09/29/2015	2017/01970	08/28/2019			DEVICE AND METHOD FOR DISPENSING A DRUG
GERMANY	GRANTED	15779121.1	09/29/2015	3200863	11/04/2020	3200863	08/09/2017	DEVICE AND METHOD FOR DISPENSING A DRUG
SPAIN	GRANTED	15779121.1	09/29/2015	3200863	11/04/2020	3200863	08/09/2017	DEVICE AND METHOD FOR DISPENSING A DRUG
FRANCE	GRANTED	15779121.1	09/29/2015	3200863	11/04/2020	3200863	08/09/2017	DEVICE AND METHOD FOR DISPENSING A DRUG
UNITED KINGDOM	GRANTED	15779121.1	09/29/2015	3200863	11/04/2020	3200863	08/09/2017	DEVICE AND METHOD FOR DISPENSING A DRUG
ITALY	GRANTED	502021000008525	09/29/2015	3200863	11/04/2020	3200863	08/09/2017	DEVICE AND METHOD FOR DISPENSING A DRUG
USA	GRANTED	16/320999	01/25/2019	10906871	02/02/2021	US-2019-0161443-A1	05/30/2019	PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS
USA	GRANTED	17/145109	01/08/2021	11352323	06/07/2022	US-2021-0130289-A1	05/06/2021	PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS
EPO PATENT	GRANTED	17757600.6	08/01/2017	3494106	07/20/2022	3494106	06/12/2019	PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
FRANCE	GRANTED	17757600.6	08/01/2017	3494106	07/20/2022	3494106	06/12/2019	PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS
GERMANY	GRANTED	17757600.6	08/01/2017	3494106	07/20/2022	3494106	06/12/2019	PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS
LIECHTENSTEIN	GRANTED	17757600.6	08/01/2017	3494106	07/20/2022	3494106	06/12/2019	PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS
LUXEMBOURG	GRANTED	17757600.6	08/01/2017	3494106	07/20/2022	3494106	06/12/2019	PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS
SWITZERLAND	GRANTED	17757600.6	08/01/2017	3494106	07/20/2022	3494106	06/12/2019	PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS
UNITED KINGDOM	GRANTED	17757600.6	08/01/2017	3494106	07/20/2022	3494106	06/12/2019	PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS
JAPAN	GRANTED	2019-503315	08/01/2017	7161466	10/18/2022	2019-524752	09/05/2019	PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS
USA	GRANTED	14/830638	08/19/2015	9926270	03/27/2018	US-2016-0052879-A1	02/25/2016	PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE
USA	GRANTED	12/795164	06/07/2010	8343945	01/01/2013	US2010-0310476A1	12/09/2010	CARRIERS, FORMULATIONS, METHODS FOR FORMULATING UNSTABLE ACTIVE AGENTS FOR EXTERNAL APPLICATION AND USES THEREOF

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
USA	GRANTED	13/732024	12/31/2012	9161916	10/20/2015	US2013-0189191A1	07/25/2013	CARRIERS, FORMULATIONS, METHODS FOR FORMULATING UNSTABLE ACTIVE AGENTS FOR EXTERNAL APPLICATION AND USES THEREOF
USA	GRANTED	12/795213	06/07/2010	8900553	12/02/2014	US2011-0212033A1	09/01/2011	OIL AND LIQUID SILICONE FOAMABLE CARRIERS AND FORMULATIONS
USA	GRANTED	14/504942	10/02/2014	9549898	01/24/2017	US2015-0118164A1	04/30/2015	OIL AND LIQUID SILICONE FOAMABLE CARRIERS AND FORMULATIONS
USA	GRANTED	15/999088	08/17/2018	11433025	09/06/2022	US-2019-0091149-A1	03/28/2019	OIL FOAMABLE CARRIERS AND FORMULATIONS
USA	GRANTED	13/123213	07/18/2011	8518376	08/27/2013	US2011-0268665A1	11/03/2011	OIL-BASED FOAMABLE CARRIERS AND FORMULATIONS
USA	GRANTED	13/967546	08/15/2013	9795564	10/24/2017	US2014-0050673A1	02/02/2014	OIL-BASED FOAMABLE CARRIERS AND FORMULATIONS
CANADA	GRANTED	2760186	10/26/2011	2760186	10/29/2019	2760186	11/04/2010	FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS COMPRISING APROTIC POLAR SOLVENTS AND USES THEREOF
USA	GRANTED	15/639114	06/30/2017	9884017	02/06/2018	US-2017-0360705-A1	12/21/2017	FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS COMPRISING APROTIC POLAR SOLVENTS AND USES THEREOF
USA	GRANTED	15/883134	01/30/2018	10213384	02/26/2019	US-2018-0153804-A1	06/07/2018	FOAMABLE VEHICLES AND PHARMACEUTICAL COMPOSITIONS COMPRISING APROTIC POLAR SOLVENTS AND USES THEREOF

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
USA	GRANTED	16/236704	12/31/2018	10363216	07/30/2019	US-2019-0201339-A1	07/04/2019	FOAMABLE VEHICLES AND PHARMACEUTICAL COMPOSITIONS COMPRISING APROTIC POLAR SOLVENTS AND USES THEREOF
USA	GRANTED	16/443649	06/17/2019	10588858	03/17/2020	US-2020-0016077-A1	01/16/2020	FOAMABLE VEHICLES AND PHARMACEUTICAL COMPOSITIONS COMPRISING APROTIC POLAR SOLVENTS AND USES THEREOF
CANADA	GRANTED	2769625	01/30/2012	2769625	04/11/2017	2769625	02/03/2011	NON SURFACTANT HYDRO-ALCOHOLIC FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND THEIR USES - CANADA
ISRAEL	GRANTED	217783	01/26/2012	217783	12/01/2016		08/31/2016	NON SURFACTANT HYDRO-ALCOHOLIC FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND THEIR USES
USA	GRANTED	13/359709	01/27/2012	9167813	10/27/2015	20120213709	08/23/2012	NON SURFACTANT HYDRO-ALCOHOLIC FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND THEIR USES
USA	GRANTED	14/857282	09/17/2015	9572775	02/21/2017	US-2016-0101051-A1	04/14/2016	NON SURFACTANT HYDRO-ALCOHOLIC FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND THEIR USES
USA	GRANTED	15/401743	01/09/2017	10092588	10/09/2018	US-2017-0216334-A1	08/03/2017	FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND THEIR USES

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
USA	GRANTED	16/108799	08/22/2018	11219631	01/11/2022	US-2019-0054106-A1	02/21/2019	FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND THEIR USES
USA	GRANTED	13/499501	09/10/2012	8945516	02/03/2015	US2013-0064777A1	03/14/2013	SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS AND BREAKABLE FOAMS AND THEIR USES - US
AUSTRALIA	GRANTED	2010302350	05/01/2012	2010302350	10/01/2015		05/24/2012	SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS AND BREAKABLE FOAMS AND THEIR USES - AUSTRALIA
CANADA	GRANTED	2776366	04/02/2012	2776366	07/18/2017	2776366	04/07/2011	SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS AND BREAKABLE FOAMS AND THEIR USES
ISRAEL	GRANTED	218861	03/27/2012	218861	05/01/2016			SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS AND BREAKABLE FOAMS AND THEIR USES - ISRAEL
SOUTH AFRICA	GRANTED	2012/03165	05/02/2012	2012/03165	07/31/2013			SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS AND BREAKABLE FOAMS AND THEIR USES - SOUTH AFRICA
AUSTRALIA	GRANTED	2015224534	09/11/2015	2015224534	09/21/2017			SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS AND BREAKABLE FOAMS AND THEIR USES - AUSTRALIA
USA	GRANTED	14/850655	09/10/2015	10238746	03/26/2019	US2016-0101184A1	04/14/2016	SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
USA	GRANTED	15/915386	03/08/2018	10137200	11/27/2018	US-2018-0193469-A1	07/12/2018	SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES
USA	GRANTED	16/235986	12/28/2018	10946101	03/16/2021	US-2019-0134204-A1	05/09/2019	SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES
USA	GRANTED	13/499475	09/14/2012	8871184	10/28/2014	US2013-0028850A1	01/31/2013	TOPICAL TETRACYCLINE COMPOSITIONS
CANADA	GRANTED	2776474	04/02/2012	2776474	01/12/2021	2776474	04/07/2011	TOPICAL TETRACYCLINE COMPOSITIONS
EPO PATENT	GRANTED	10819992.8	04/30/2012	2482788	12/14/2022	2482788	08/08/2012	TOPICAL TETRACYCLINE COMPOSITIONS - EUROPE
BELGIUM	GRANTED	10819992.8	04/30/2012	2482788	12/14/2022	2482788	08/08/2012	TOPICAL TETRACYCLINE COMPOSITIONS - EUROPE
FRANCE	GRANTED	10819992.8	04/30/2012	2482788	12/14/2022	2482788	08/08/2012	TOPICAL TETRACYCLINE COMPOSITIONS - EUROPE
GERMANY	GRANTED	10819992.8	04/30/2012	2482788	12/14/2022	2482788	08/08/2012	TOPICAL TETRACYCLINE COMPOSITIONS - EUROPE
IRELAND	GRANTED	10819992.8	04/30/2012	2482788	12/14/2022	2482788	08/08/2012	TOPICAL TETRACYCLINE COMPOSITIONS - EUROPE
LUXEMBOURG	GRANTED	10819992.8	04/30/2012	2482788	12/14/2022	2482788	08/08/2012	TOPICAL TETRACYCLINE COMPOSITIONS - EUROPE
SWITZERLAND	GRANTED	10819992.8	04/30/2012	2482788	12/14/2022	2482788	08/08/2012	TOPICAL TETRACYCLINE COMPOSITIONS - EUROPE
UNITED KINGDOM	GRANTED	10819992.8	04/30/2012	2482788	12/14/2022	2482788	08/08/2012	TOPICAL TETRACYCLINE COMPOSITIONS - EUROPE
UNITED KINGDOM	GRANTED	1016546.2	10/01/2010	2474930	07/04/2012	2474930	05/04/2011	(MONITOR ONLY) TOPICAL TETRACYCLINE COMPOSITIONS - UNITED KINGDOM
ISRAEL	GRANTED	218865	03/27/2012	218865	05/29/2017		02/28/2017	TOPICAL TETRACYCLINE COMPOSITIONS - ISRAEL
MEXICO	GRANTED	MX/A/2012/003985	04/02/2012	359879	10/12/2018			TOPICAL TETRACYCLINE COMPOSITIONS



Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
USA	GRANTED	14/327040	07/09/2014	8865139	10/21/2014	US2014-0328770A1	11/06/2014	TOPICAL TETRACYCLINE COMPOSITIONS - US
USA	GRANTED	14/469792	08/27/2014	8992896	03/31/2015	US2015-0056149A1	02/26/2015	TOPICAL TETRACYCLINE COMPOSITIONS
USA	GRANTED	14/595882	01/13/2015	9675700	06/13/2017	US2015-0190409A1	07/09/2015	TOPICAL TETRACYCLINE COMPOSITIONS
USA	GRANTED	15/591733	05/10/2017	10213512	02/26/2019	US-2017-0340743-A1	11/30/2017	TOPICAL TETRACYCLINE COMPOSITIONS
USA	GRANTED	15/913574	03/06/2018	10086080	10/02/2018	US-2018-0193468-A1	07/12/2018	TOPICAL TETRACYCLINE COMPOSITIONS
USA	GRANTED	16/235964	12/28/2018	10322186	06/18/2019	US-2019-0134203-A1	05/09/2019	TOPICAL TETRACYCLINE COMPOSITIONS
USA	GRANTED	16/387407	04/17/2019	10463742	11/05/2019	US-2019-0262456-A1	08/29/2019	TOPICAL TETRACYCLINE COMPOSITIONS
USA	GRANTED	16/578252	09/20/2019	10610599	04/07/2020	US-2020-0016271-A1	01/16/2020	TOPICAL TETRACYCLINE COMPOSITIONS
USA	GRANTED	13/499709	09/10/2012	10029013	07/24/2018	US2013-0011342A1	01/10/2013	SURFACTANT-FREE, WATER-FREE FORMABLE COMPOSITION AND BREAKABLE FOAMS AND THEIR USES
CANADA	GRANTED	2776471	04/02/2012	2776471	02/12/2019	2776471	06/03/2011	SURFACTANT-FREE, WATER-FREE FOAMABLE COMPOSITIONS AND BREAKABLE FOAMS AND THEIR USES - CANADA
ISRAEL	GRANTED	218866	03/27/2012	218866	05/29/2018		02/28/2018	SURFACTANT-FREE, WATER-FREE FOAMABLE COMPOSITIONS AND BREAKABLE FOAMS AND THEIR USES
USA	GRANTED	16/019623	06/27/2018	10967063	04/06/2021	US-2019-0000980-A1	01/03/2019	SURFACTANT-FREE, WATER-FREE FORMABLE COMPOSITION AND BREAKABLE FOAMS AND THEIR USES
CANADA	GRANTED	2776482	04/02/2012	2776482	06/07/2022	2776482	11/10/2011	COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
USA	GRANTED	13/100724	05/04/2011	8618081	12/31/2013	US2011-0281827A1	11/17/2011	COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF
USA	GRANTED	14/078746	11/13/2013	10265404	04/23/2019	US2014-0066524A1	03/06/2014	COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF
USA	GRANTED	16/280921	02/20/2019	10821187	11/03/2020	US-2019-0231886-A1	08/01/2019	COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF
USA	GRANTED	16/387381	04/17/2019	10835613	11/17/2020	US-2019-0275157-A1	09/12/2019	COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF
CANADA	GRANTED	2867419	09/12/2014	2867419	10/24/2023	2867419	09/19/2013	TOPICAL APPLICATIONS AND FORMULATIONS
USA	GRANTED	13/831396	03/14/2013	9849142	12/26/2017	US2013-0225536A1	08/29/2013	METHODS FOR ACCELERATED RETURN OF SKIN INTEGRITY AND FOR THE TREATMENT OF IMPETIGO
USA	GRANTED	15/816850	11/17/2017	10517882	12/31/2019	US-2018-0147218-A1	05/31/2018	METHOD FOR HEALING OF AN INFECTED ACNE LESION WITHOUT SCARRING
MEXICO	GRANTED	MX/A/2018/002067	08/19/2016	399368	01/19/2023			TETRACYCLINE MANAGEMENT OF EGFR INHIBITOR ASSOCIATED DERMATOSSES
USA	GRANTED	15/699692	09/08/2017	10398641	09/03/2019	2018-0064638-A1	03/08/2018	COMPOSITIONS AND METHODS FOR TREATING ROSACEA AND ACNE
MEXICO	GRANTED	MX/A/2017/011630	09/08/2017	377365	11/13/2020			COMPOSITIONS AND METHODS FOR TREATING ROSACEA

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
USA	GRANTED	16/508611	07/11/2019	10849847	12/01/2020	US-2020-0016068-A1	01/16/2020	COMPOSITIONS AND METHODS FOR TREATING ROSACEA AND ACNE
MEXICO	GRANTED	MX/A/2020/012139	11/12/2020	402876	05/25/2023			COMPOSITIONS AND METHODS FOR TREATING ROSACEA
USA	GRANTED	17/075217	10/20/2020	11324691	05/10/2022	US-2021-0205212-A1	07/08/2021	COMPOSITIONS AND METHODS FOR TREATING ROSACEA AND ACNE

(End of Owned Patents)

**Owned Patent Applications**

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
EPO PATENT	PENDING	21154651.0	02/28/2014			3842419	06/30/2021	GLYCOPYRROLATE SALTS
ISRAEL	PENDING	278152	02/28/2014					GLYCOPYRROLATE SALTS
MEXICO	PENDING	MX/A/2020/002544	02/28/2014			MX/A/2020/002544	08/13/2020	GLYCOPYRROLATE SALTS
CANADA	PENDING	3030772	08/01/2017			3030772		PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS
HONG KONG	PENDING	19133462.2	08/01/2017			40010076	07/03/2020	PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS
USA	PENDING	17/506343	10/20/2021			US-2022-0118236-A1	04/21/2022	ROLL-ON APPLICATORS AND METHODS FOR TREATING DERMAL CONDITIONS
USA	PENDING	17/844715	06/20/2022			2023-0131030	04/27/2023	METHODS FOR TREATING INFLAMMATORY SKIN CONDITIONS
HONG KONG	PENDING	42021045527.5	02/28/2014			40055842	03/18/2022	GLYCOPYRROLATE SALTS
USA	PENDING	17/713221	04/04/2022			US-2022-0233500-A1	07/28/2022	GLYCOPYRROLATE SALTS
USA	PENDING	17/774850	05/05/2022			US-2022-0401412-A1	12/22/2022	METHODS FOR PALMAR OR PLANTAR ADMINISTRATION OF PHARMACEUTICAL COMPOSITIONS
JAPAN	PENDING	2022-525169	11/04/2020			2022-554264	12/28/2022	METHODS FOR PALMAR OR PLANTAR ADMINISTRATION OF PHARMACEUTICAL COMPOSITIONS
JAPAN	PENDING	2022-165169	10/14/2022			2022-191407	12/27/2022	PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
USA	PENDING	18/142,409	05/02/2023					TOPICAL GLYCOPYRROLATE FORMULATIONS
USA	PENDING	17/819444	08/12/2022					OIL FOAMABLE CARRIERS AND FORMULATIONS
USA	PENDING	17/661467	04/29/2022					FOAMABLE VEHICLES AND PHARMACEUTICAL COMPOSITIONS COMPRISING APROTIC POLAR SOLVENTS AND USES THEREOF
USA	PENDING	18/063125	12/08/2022					FOAMABLE VEHICLES AND PHARMACEUTICAL COMPOSITIONS COMPRISING APROTIC POLAR SOLVENTS AND USES THEREOF
USA	PENDING	17/814894	07/26/2022					FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND THEIR USES
INDIA	PENDING	882/KOLNP/2012	10/01/2010					SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS AND BREAKABLE FOAMS AND THEIR USES - ISRAEL
USA	PENDING	16/948631	09/25/2020			US-2021-0015927-A1	01/21/2021	SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES
USA	PENDING	16/805201	02/28/2020			US-2020-0261586-A1	08/20/2020	TOPICAL TETRACYCLINE COMPOSITIONS
USA	PENDING	17/066752	10/09/2020			US-2021-0023226-A1	01/28/2021	SURFACTANT-FREE, WATER-FREE FORMABLE COMPOSITION AND BREAKABLE FOAMS AND THEIR USES

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
USA	PENDING	18/157346	01/20/2023					SURFACTANT-FREE, WATER-FREE FOAMABLE COMPOSITION AND BREAKABLE FOAMS AND THEIR USES
USA	PENDING	18/464,631	09/11/2023					SURFACTANT-FREE, WATER-FREE FOAMABLE COMPOSITION AND BREAKABLE FOAMS AND THEIR USES
USA	PENDING	17/806354	06/10/2022					COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES
USA	PENDING	18/153604	01/12/2023					COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES
USA	PENDING	18/472,825	09/22/2023					COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES
USA	PENDING	17/804121	05/26/2022					COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF
USA	PENDING	17/804141	05/26/2022					COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF
USA	PENDING	18/150037	01/04/2023					COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF
USA	PENDING	18/153414	01/12/2023					COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF
USA	PENDING	18/456,612	08/28/2023					COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
USA	PENDING	18/462,080	09/06/2023					COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF
USA	PENDING	17/025156	09/18/2020			US-2021-0077509-A1	03/18/2021	COMPOSITIONS FOR THE IMPROVED TREATMENT OF ACNE AND RELATED DISORDERS
USA	PENDING	17/660345	04/22/2022					METHODS FOR ACCELERATED RETURN OF SKIN INTEGRITY AND FOR THE TREATMENT OF IMPETIGO
USA	PENDING	17/936562	09/29/2022			2023-0270760	08/31/2023	COMPOSITIONS FOR THE IMPROVED TREATMENT OF ACNE AND RELATED DISORDERS
USA	PENDING	18/055902	11/16/2022					METHODS FOR ACCELERATED RETURN OF SKIN INTEGRITY AND FOR THE TREATMENT OF IMPETIGO
CANADA	PENDING	2995794	08/19/2016			2995794	02/23/2017	TETRACYCLINE MANAGEMENT OF EGFR INHIBITOR ASSOCIATED DERMATOSES
USA	PENDING	17/814562	07/25/2022					TETRACYCLINE MANAGEMENT OF EGFR INHIBITOR ASSOCIATED DERMATOSES
USA	PENDING	18/177472	03/02/2023					TETRACYCLINE MANAGEMENT OF EGFR INHIBITOR ASSOCIATED DERMATOSES
CANADA	PENDING	2978573	09/08/2017			2978573	03/08/2018	COMPOSITIONS AND METHODS FOR TREATING ROSACEA

Country	Status	Application Number	Filing Date	Patent Number	Issue Date	Publication Number	Publication Date	Title
USA	PENDING	17/657638	04/01/2022					COMPOSITIONS AND METHODS FOR TREATING ROSACEA AND ACNE
USA	PENDING	18/052822	11/04/2022					COMPOSITIONS AND METHODS FOR TREATING ROSACEA AND ACNE
USA	PENDING	18/363,358	08/01/2023					COMPOSITIONS AND METHODS FOR TREATING ROSACEA AND ACNE
USA	PENDING	16/624244	06/19/2018			2023-0123488	04/20/2023	STABLE TOPICAL TETRACYCLINE COMPOSITIONS
CANADA	PENDING	3067308	06/19/2018			3067308	12/27/2018	STABLE TOPICAL TETRACYCLINE COMPOSITIONS
USA	PENDING	17/597892	01/28/2022			2023-0346805	11/02/2023	COMPOSITIONS AND METHODS AND USES THEREOF
EPO PATENT	PENDING	20757153.0	07/30/2020			4003302	06/01/2022	COMPOSITIONS AND METHODS AND USES THEREOF
TAIWAN	PENDING	109126107	07/31/2020					COMPOSITIONS AND METHODS AND USES THEREOF

(End of Owned Patent Applications)







**Trademarks**





See attached.




**TRADEMARK REGISTRATIONS**

<u>Trademark</u>	<u>Reg. No./Serial No.</u>	<u>Reg. Date</u>	<u>Record Owner</u>
Accutane®	5788124 87003385	06/25/2019	Journey Medical Corporation

**AMZEEQ and AMZEEQ Drop Logos**

<b>Country</b>	<b>Mark</b>	<b>Status</b>	<b>App. No.</b>	<b>Reg. No.</b>	<b>Class</b>
Brazil	AMZEEQ	Registered	917719220	917719220	5
Brazil	AMZEEQ Drop Logo 	Registered	917643038	917643038	5
Canada	AMZEEQ	Pending	1983656 (IR)		5
Canada	AMZEEQ Drop Logo 	Pending	1983656 (IR)		5
China	AMZEEQ	Registered	1485598	1485598	5
China	AMZEEQ Drop Logo 	Registered	1494994	1494994	5
European Union	AMZEEQ	Registered	1485598	1485598	5
European Union	AMZEEQ Drop Logo 	Registered	1494994	1494994	5
Israel	AMZEEQ	Registered	320238 (IR)	320238 (IR)	5


Country	Mark	Status	App. No.	Reg. No.	Class
Israel	AMZEEQ Drop Logo 	Registered	321882 (IR)	321882 (IR)	5
Mexico	AMZEEQ	Registered	1485598	1485598	5
Mexico	AMZEEQ Drop Logo 	Registered	1494994	1494994	5
Russia	AMZEEQ	Registered	1485598	1485598	5
Russia	AMZEEQ Drop Logo 	Registered	1494994	1494994	5
Taiwan	AMZEEQ	Pending	109070374		5
Taiwan	AMZEEQ Drop Logo 	Pending	109070375		5
United Kingdom	AMZEEQ	Registered	1485598	1485598	5
United Kingdom	AMZEEQ Drop Logo	Registered	1494994	1494994	5


Country	Mark	Status	App. No.	Reg. No.	Class
					
United States of America  <b>**Registered with CBP**</b>	AMZEEQ	Registered	87554383	6024563	5
United States of America	AMZEEQ Full Logo  	Registered	88246823	6034819	5
United States of America  <b>**Registered with CBP**</b>	AMZEEQ Drop Logo  	Registered	88246829	6034820	5

## TRADEMARK REGISTRATIONS

<u>Trademark</u>	<u>Reg. No./Serial No.</u>	<u>Reg. Date</u>	<u>Record Owner</u>
Eurax®	5227868 87239614	06/20/2017	Journey Medical Corporation
Eurax®	0434497 71522777	11/18/1947	Journey Medical Corporation


**MST, MST Logo, and MOLECULE STABILIZING TECHNOLOGY (MST)**

<b>Country</b>	<b>Mark</b>	<b>Status</b>	<b>App. No.</b>	<b>Reg. No.</b>	<b>Class</b>
Brazil	MST	Registered	918007534	918007534	3
Brazil	MST	Registered	918007569	918007569	5
Canada	MST	Pending	1998144 (IR)		3, 5
China	MST	Pending	48372217		5
European Union	MST	Registered	1500011	1500011	3, 5
Israel	MOLECULE STABILIZING TECHNOLOGY (MST)	Registered	329186	329186	5
Israel	MST	Registered	322753 (IR)	322753 (IR)	3, 5
Israel	MST Logo 	Pending	342610		5
Mexico	MST	Registered	2301367 (IR)	2301367 (IR)	3
Mexico	MST	Pending	2301368 (IR)		5
Russia	MOLECULE STABILIZING TECHNOLOGY (MST)	Pending	2020776924		5
United Kingdom	MST	Registered	1500011	1500011	3, 5
United States of America	MST	Pending	88308081		3,5

United States of America	MST Logo 	Pending	90892398		5
--------------------------	---	---------	----------	--	---



**TRADEMARK REGISTRATIONS**




<u>Trademark</u>	<u>Reg. No./Serial No.</u>	<u>Reg. Date</u>	<u>Record Owner</u>
Journey Medical Corporation®	5069478 86595147	10/25/2016	Journey Medical Corporation
 ®	5027634 86369338	08/23/2016	Journey Medical Corporation
Targadox®	5101104 86592346	12/13/2016	Journey Medical Corporation
TARGADOX®	5096340 86619982	12/06/2016	Journey Medical Corporation
Ximino®	5370300 86210940	01/02/2018	Journey Medical Corporation
Capsular Minotab Technology®	6084244 88689547	06/30/2020	Journey Medical Corporation
Accutane®	5788124 87003385	06/25/2019	Journey Medical Corporation
Eurax®	5227868 87239614	06/20/2017	Journey Medical Corporation
Eurax®	0434497 71522777	11/18/1947	Journey Medical Corporation
Ceracade®	5096785 86761118	12/06/2016	Journey Medical Corporation





Luxamend®	5042776 86776565	09/13/2016	Journey Medical Corporation
Journey Total Access Program™	Common law	Common law	Journey Medical Corporation




## TRADEMARK REGISTRATIONS



<u>Trademark</u>	<u>Reg. No./Serial No.</u>	<u>Reg. Date</u>	<u>Record Owner</u>
Targadox®	5101104 86592346	12/13/2016	Journey Medical Corporation
TARGADOX®	5096340 86619982	12/06/2016	Journey Medical Corporation

**ZILXI and Pebble Designs (color and black & white)**


<b>Country</b>	<b>Mark</b>	<b>Status</b>	<b>App. No.</b>	<b>Reg. No.</b>	<b>Class</b>
Brazil	ZILXI	Registered	920131670	920131670	5
Brazil	Pebble Design (Black and White) 	Registered	919972110	919972110	5
Canada	ZILXI	Pending	2063339 (IR)		5
Canada	Pebble Design (Black and White) 	Pending	2041550 (IR)		5
China	ZILXI	Registered	1559645	1559645	5
China	Pebble Design (Color) 	Pending	47493954		5
China	Pebble Design (Black and White)	Registered	1542150	1542150	5

Country	Mark	Status	App. No.	Reg. No.	Class
					
European Union	ZILXI	Registered	1559645	1559645	5
European Union	Pebble Design (Black and White) 	Registered	1542150	1542150	5
Israel	ZILXI	Registered	333350 (IR)	333350 (IR)	5
Israel	Pebble Design (Black and White) 	Registered	329905 (IR)	329905 (IR)	5
Mexico	ZILXI	Pending	1559645		5
Mexico	Pebble Design (Black and White) 	Pending	1542150		5
Russia	ZILXI	Pending	1559645		5

Country	Mark	Status	App. No.	Reg. No.	Class
Russia	Pebble Design (Black and White) 	Registered	1542150	1542150	5
Taiwan	ZILXI	Pending	109046889		5
Taiwan	Pebble Design (Black and White) 	Registered	109041701	02121013	5
United Kingdom	ZILXI	Registered	1559645	1559645	5
United Kingdom	Pebble Design (Black and White) 	Registered	1542150	1542150	5
United States of America	ZILXI	Registered	88758482	6235231	5
United States of America	Pebble Design (Color)	Registered	88737079	6223434	5
<b>**Registered with CBP**</b>					

Country	Mark	Status	App. No.	Reg. No.	Class
					
United States of America  <b>**Registered with CBP**</b>	Pebble Design (Black and White)  	Registered	88737293	6223436	5

### Trademarks and Trademark Applications

Loan Party	Mark (Text)	Serial Number	Application Date	Registration Number	Registration Date
Journey Medical Corporation	QBREXZA	87745446	Jan. 05, 2018	5639520	Dec. 25, 2018
Journey Medical Corporation	EXELDERM	73304315	Apr. 06, 1981	1206693	Aug. 31, 1982
Journey Medical Corporation	 (fingerprint design)	90094124	August 5, 2020	6505432	October 5, 2021